Xconomy
JANUARY 2, 2017
That being said, here’s what I’ll be keeping an eye on in Washington in 2017. When I worked in the Reagan Administration, the “Gipper” used to handle questions like this by saying he couldn’t respond to hypothetical questions. Overall, the bill will.
Xconomy
FEBRUARY 12, 2018
As president-elect, Donald Trump in January 2017 slammed drug companies for “getting away with murder” and said he supported Medicare negotiation. He vowed during last month’s State of the Union speech that drug prices “will come down.” The first is drug importation—bringing in cheaper products from.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
JULY 20, 2018
After nearly two years of all smoke, no fire around President Trump’s promise to curtail drug prices, there’s finally some glimmer of action. Pfizer said last week it would halt its price hikes, and Novartis and Merck took similar actions this week. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Xconomy
JANUARY 5, 2018
Hopefully a lot less hatred, greed, stupidity, and angst than 2017. Two other big questions we raised immediately became topics of conversation this week, thanks to Spark Therapeutics, which set the price for its gene therapy—the first ever approved in the U.S.—at Welcome to the new year. What will it bring?
Xconomy
APRIL 23, 2019
After a breakout year in 2017, the blockchain sector suffered a series of blows in 2018, from crashing cryptocurrency prices to increased regulatory scrutiny of crypto ventures and deepening skepticism about whether the technology was actually useful.
Xconomy
JULY 19, 2019
In late 2017, a federal watchdog unit assigned a working group to keep an eye on cryptocurrencies such as Bitcoin, and to sound an alert if those alternate currencies showed signs of becoming a risk to the stability of the US financial system.
Xconomy
OCTOBER 5, 2018
But since then its stock price has fallen significantly, dropping below $1 per share multiple times in the past two years, which nearly got the listing booted from the Nasdaq exchange. billion in sales in 2017—said Thursday it had had agreed to buy Senomyx for $1.50 Through a U.S. per share, or.
Expert insights. Personalized for you.
74 
Let's personalize your content